VolitionRx (NYSE-A:VNRX) Limited said its Nu.Q Vet Cancer Test has been launched in Asia through SAGE Healthcare Private Limited, which was appointed as a non-exclusive licensee and distributor for the cancer test last year.
Following pre-launch preparations, SAGE hosted a launch event featuring Professor Heather Wilson-Robles, chief medical officer at Volition Veterinary, and Dr Tom Butera, chief executive officer at Volition Veterinary on Friday, April 22.
SAGE is now actively marketing the test and will be processing samples and providing test results from its centralized lab with immediate effect.
"Over half of the Asian population have a companion animal, with almost a third of households owning a dog. We believe that the opportunity for the Nu.Q Vet Cancer Test is huge,” said Dr Jasmine Kway, chief executive officer of Singapore Volition in a statement.
READ: VolitionRx appoints industry veteran Sharon Ballesteros as its US head of quality and development process
“SAGE Healthcare is one of the strongest and most respected distributors of leading veterinary brands in Singapore and we are delighted that the launch event was so well attended, and that active sales and marketing efforts are now underway," Kway added.
"Adding the Nu.Q Vet Cancer Test to the routine wellness check-up for older dogs and at-risk breeds could help detect cancer early, when treatment is more effective and affordable. We believe that this is a clear unmet need in the veterinary space," commented Irene Kum, general manager for SAGE Healthcare.
"We are excited to launch the test in Singapore and hope to develop subsequent launch plans in other Asian markets in the future."
VolitionRx (NYSE-A:VNRX) is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals.
Contact the author at jon.hopkins@proactiveinvestors.com